Skip to main content

Table 2 Incidence of transient liver function impairment (TLI) and drug-induced liver injury (DILI) during anti-tuberculous treatment in different patient groups

From: Hepatitis C and not Hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury

 

Control

(n=251)

HBV

(n=83)

P-value*

HCV

(n=41)

P-value†

HBV+HCV

(n=4)

P-value‡

TLI

27 (10.8)

18 (21.7)

0.010

9 (22.0)

0.040

1 (25.0)

0.310

DILI

25 (10.0)

11 (13.3)

0.400

13 (31.7)

<0.001

3 (75.0)

0.002

Mild

12 (4.8)

2( 2.4)

 

7 (17.1)

 

2 (50.0)

 

Moderate

8 (3.2)

6 (7.2)

 

5 (12.2)

 

1 (25.0)

 

Severe

5 (2.0)

3 (3.6)

 

1 (2.4)

 

0 (0)

 
  1. HBV: hepatitis B virus, HCV: hepatitis C virus
  2. *P-value: Control vs. HBV group
  3. †P-value: Control vs. HCV group
  4. ‡P-value: Control vs. HBV+HCV group
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us